SCHEMBL5135490

SCHEMBL5135490

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(=O)OC)cc1)Cc1ccc(N(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 3/20 0.43
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 2/20 0.41
NPC1 O15118 2/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
AGTR1 P30556 4/20 0.40
C5AR1 P21730 1/20 0.40
DRD2 P14416 1/20 0.39
TBXA2R P21731 1/20 0.39
MAPT P10636 5/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TP53 P04637 1/20 0.39
MCL1 Q07820 1/20 0.39
SIRT1 Q96EB6 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137376 0.94 C5AR1 (0.42) ALDH1A1KDM4EGAATSHRAGTR1
SCHEMBL4770661 0.91 C5AR1 (0.42) SIRT2ALDH1A1GAAMAPK1TSHR
SCHEMBL5137399 0.91 GAA (0.43) SIRT2ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL5135950 0.90 LPAR1 (0.42) ALDH1A1KDM4EGAAAGTR1C5AR1
SCHEMBL5135770 0.88 C5AR1 (0.46) ALDH1A1SMN1; SMN2KDM4EGAAMAPK1
SCHEMBL5135457 0.87 TRPM8 (0.44) ALDH1A1KDM4EGAAHPGDAGTR1
SCHEMBL5136530 0.87 C5AR1 (0.41) AGTR1C5AR1TP53
SCHEMBL5135104 0.86 C5AR1 (0.44) SIRT2ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL650281 0.86 AGTR1 (0.40) ALDH1A1KDM4ETSHRAGTR1C5AR1
SCHEMBL5137576 0.86 TLR7 (0.47) C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed